



501-3292 Production Way, Burnaby, B.C., V5A 4R4

Phone: (604) 551-7831 Fax: 604-676-2767

info@cannabixtechnologies.com

cannabixtechnologies.com

Cannabix Technologies Enters into Marketing Agreements

Vancouver, British Columbia, May 13, 2024 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports that it has entered into an arm’s length marketing agreements with the following parties:

Effective May 13, 2024, the Company has engaged Financial Buzz Media Networks LLC (“FBMN”) for fees of \$10,000 USD for a 30-day term. The Company may elect to renew the engagement at any point during the term. The Services will include, but are not limited to, video news recaps covering latest news releases and press release editorial syndication. Consideration paid to FBMN does not include any securities of the Company (address: 3 Columbus Circle 15th Floor, New York, 877-601-1879).

The Company has engaged aktiencheck.de AG (“aktiencheck”) for a fee of 20,000 euros for a 30-day term effective May 2, 2024. The Company may elect to extend the engagement at any point during the term. The Services will include, but are not limited to editorial write-ups, translation, search engine marketing, native advertising and email marketing. Consideration paid to aktiencheck does not include any securities of the Company (address: Bahnhofstr. 6, 56470 Bad Marienberg, Germany, info@aktiencheck.de).

The Company has engaged InvestorsHub.com Inc. (“InvestorsHub”) for news release dissemination services for a fee of \$4,800 USD effective May 7, 2024 until the budget is exhausted. The Company may elect to renew the engagement in the future. Consideration paid to InvestorsHub does not include any securities of the Company (address: PO Box 780, Harrisonville, MO 6470, 888-498-5839).

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is developing delta-9 THC and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana that causes impairment. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of its Breath Logix Series of breath alcohol detection devices for employers and a range of other settings.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that its development of breathalyzer technology will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. There is no assurance that evaluators of the Company's breathalyzer technology will agree or come to terms on distribution or enter into a sales agreement, of any kind. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.